Franklin Lakes, New Jersey-based BD’s acquisition of the Leeds, United Kingdom-based company aims to expand global offerings for surgeons outside the U.S. with Tissuemed’s lead product, Tissuepatch.
Tissuemed designed Tissuepatch as a proprietary sealant technology that bonds tissue to help control internal bleeding or prevent leaks from surgical incisions, according to a news release. The company said it made Tissuepatch’s thin, flexible and transparent composition ready for use out of the package, making it ideal for a range of surgical sealant applications.
BD said surgeons already trust Tissuepatch with its design for enabling strong adhesive and minimal swelling, giving the company an opportunity to leverage its reach and clinical expertise to continue making strides in sealant technologies.
The company noted that it expects the transaction to be immaterial to its fiscal 2022 results.
“This advanced sealant serves as a strategic complement to the BD products used in the operating room today — providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions,” BD President of Surgery Kevin Kelly said in the release. “Integrating Tissuepatch™ into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries.”